Vaccine candidates for leishmaniasis: A review

International Immunopharmacology

Volumn 11, Issue 10, 2011, Pages 1464-1488

  Nagill, Rajeev ^a   Kaur, Sukhbir ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Adjuvant; Antigen; Immune response; Leishmaniasis; Vaccines

Indexed keywords

AMASTIGOTE ANTIGEN; ANTIGEN; CYSTEINE PROTEINASE; DNA VACCINE; FUCOSE MANNOSE LIGAND; GLUCOSE REGULATED PROTEIN 78; GLYCOPROTEIN; GLYCOPROTEIN 46; GLYCOPROTEIN 63; HISTONE H1; HYDROPHILIC ACYLATED SURFACE PROTEIN B1; INACTIVATED VACCINE; KILLED LEISHMANIA VACCINE; KINETOPLASTID MEMBRANE PROTEIN 11; LCR1 PROTEIN; LEISHMANIA VACCINE; LIGAND; LIVE ATTENUATED LEISHMANIA VACCINE; LIVE VACCINE; MURAMYL DIPEPTIDE; PARAFLAGELLAR ROD PROTEIN 2; POLYPROTEIN VACCINE; PROMASTIGOTE SURFACE ANTIGEN 2; PROTEIN; PROTEIN DP72; PROTEIN KINASE C; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; VACCINE;

AMASTIGOTE; HUMAN; IMMUNE RESPONSE; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE VECTORS; DRUG EVALUATION, PRECLINICAL; HUMANS; LEISHMANIA; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; VACCINES, DNA;

EID: 80053251597     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.05.008     Document Type: Review

References (409)

1. M.C. Pinto, D.H. Campbell-Lendrum, A.L. Lozovei, U. Teodoro, and C.R. Davies Phlebotomine sandfly responses to carbon dioxide and human odour in the field Med Vet Entomol 15 2001 132 139 (Pubitemid 32614522)
2. C.R. Davies, P. Kaye, S.L. Croft, and S. Sundar Leishmaniasis: new approaches to disease control BMJ 326 2003 377 382 (Pubitemid 36241477)
3. A. Bryceson Tropical medicine for the 21st century. Tropical medicine should be concerned with medical problems endemic to the tropics BMJ 312 7025 1996 247
4. R. Baker, P. Chiodini, and P.M. Kaye Leishmaniasis G.D. James, A. Zumla, The granulomatous diseases 1999 Cambridge University Press Cambridge, UK 212 234
5. T.V. Piscopo, and A.C. Mallia Leishmaniasis Postgrad Med J 82 2006 649 657 (Pubitemid 44786872)
6. P.E.C. Manson-Bahr, B.A. Southgate, and A.E.C. Harvey Development of kala-azar in man after inoculation with a Leishmania from a Kenyo sandfly BMJ 1 1963 1208 1210
7. P. Desjeux Leishmaniasis: current situation and new perspectives Comp Immunol Microbiol Infect Dis 27 2004 305 318 (Pubitemid 38842803)
8. E.E. Zijlstra, and A.M. El-Hassan Leishmaniasis in Sudan. Visceral leishmaniasis Trans R Soc Trop Med Hyg 95 Suppl. 1 2001 S27 S58
9. K. Ritmeijer, and R.N. Davidson Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins Sans Frontieres interventions against kala-azar in the Sudan, 1989-2003 Trans R Soc Trop Med Hyg 97 2003 609 613
10. T. Haile, and S.D. Anderson Visceral leishmaniasis in Northern Ethiopia East Afr Med J 83 2006 389 392 (Pubitemid 44671695)
11. J. Alvar, S. Bashaye, D. Argaw, I. Cruz, P. Aparicio, and A. Kassa Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment Am J Trop Med Hyg 77 2007 275 282 (Pubitemid 351859276)
12. A. Joshi, J.P. Narain, C. Prasittisuk, R. Bhatia, G. Hashim, and A. Jorge Can visceral leishmaniasis eliminated from Asia? J Vector Borne Dis 45 2008 105 111 (Pubitemid 351809286)
13. R. Reithinger, J.L. Dujardin, H. Louzir, C. Pirmez, B. Alexander, and S. Brooker Cutaneous leishmaniasis Lancet Infect Dis 7 2007 581 596 (Pubitemid 47277438)
14. Y. Dowlati Cutaneous leishmaniasis: clinical aspects Clin Dermatol 14 1996 425 431
15. P. Machado, C. Araujo, A.T. Da Silva, R.P. Almeida, A. D'Oliveira Jr., and A. Bittencourt Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer Clin Infect Dis 34 12 2002 E69 E73
16. A.J. Magill Cutaneous leishmaniasis in the returning traveler Infect Dis Clin N Am 19 2005 241 266 (Pubitemid 40208584)
17. I. Cruz, J. Neito, J. Moreno, C. Canavate, P. Desjeux, and J. Alvar Leishmania/HIV co-infections in the second decade Indian J Med Res 123 2006 357 388 (Pubitemid 43905576)
18. C.R. Davies, R. Reithinger, D. Campbell-Lendrum, D. Feliciangeli, R. Borges, and N. Rodriguez The epidemiology and control of leishmaniasis in Andean countries Cad Saude Publica 16 2000 925 950
19. P.D. Marsden Mucosal leishmaniasis ("espundia" Escomel, 1911) Trans R Soc Trop Med Hyg 80 1986 859 876
20. T.A. Morsy, N.M. Khalil, M.M. Salama, K.N. Hamdi, Y.A. Shamrany, and K.F. Abdalla Mucosal leishmaniasis caused by Leishmania tropica in Saudi Arabia J Egypt Soc Parasitol 25 1995 73 79
21. L. Aliaga, F. Cobo, J.D. Mediavilla, J. Bravo, A. Osuna, and J.M. Amador Localized mucosal leishmaniasis due to Leishmania infantum: clinical and microbiologic findings in 31 patients Medicine (Baltimore) 82 2003 147 158 (Pubitemid 36578704)
22. M. Kharfi, B. Fazaa, E. Chaker, and M.R. Kamoun Mucosal localization of leishmaniasis in Tunisia: 5 cases Ann Dermatol Venereol 130 2003 27 30 (Pubitemid 36287924)
23. D. Gavron, and A. Saul Pioneer of tropical medicine 1997 Balaban Publishers Rehovot, Israel 0-86689-045-9
24. K.S. Tabbara, N.C. Peters, F. Afrin, S. Mendez, S. Bertholet, and Y. Belkaid Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection Infect Immun 73 2005 4714 4722 (Pubitemid 41105627)
25. A. Khamesipour, S. Rafati, N. Davoudi, F. Maboudi, and F. Modabber Leishmaniasis vaccine candidates for development: a global overview Indian J Med Res 123 3 2006 423 438 (Pubitemid 43905580)
26. F. Modabber Vaccines against leishmaniasis Ann Trop Med Parasitol 89 Suppl.1 1995 83 88 (Pubitemid 26030071)
27. L. Kedzierski, Y. Zhu, and E. Handman Leishmania vaccines: progress and problems Parasitology 133 2006 S87 S112
28. G.F. Mitchell, E. Handman, and T.W. Spithill Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection Aust J Exp Biol Med Sci 62 1984 145 153 (Pubitemid 14058198)
29. R.M. Gorczynski Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes Cell Immunol 94 1985 11 20 (Pubitemid 15247791)
30. D. Rivier, R. Shah, P. Bovay, and J. Mauel Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge Mol Biochem Parasitol 152 1993 35 46
31. P.B. Kimsey, C.M. Theodos, T.K. Mitchen, S.J. Turco, and R.G. Titus An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major Infect Immun 61 1993 5205 5213 (Pubitemid 23353899)
32. H. Daneshvar, G.H. Coombs, P. Hagan, and R.S. Phillips Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines J Infect Dis 187 2003 1662 1668 (Pubitemid 36578973)
33. J.A. Streit, T.J. Recker, F.G. Filho, S.M. Beverley, and M.E. Wilson Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms J Immunol 166 2001 1921 1929 (Pubitemid 32114679)
34. R.G. Titus, F.J. Gueiros-Filho, L.A. de Freitas, and S.M. Beverley Development of a safe live Leishmania vaccine line by gene replacement Proc Natl Acad Sci U S A 92 1995 10267 10271
35. P. Veras, C. Brodskyn, F. Balestieri, L. Freitas, A. Ramos, and A. Queiroz A dhfr-ts Leishmania major knockout mutant cross-protects against Leishmania amazonensis Mem Inst Oswaldo Cruz 94 1999 491 496 (Pubitemid 129572523)
36. V.F. Amaral, A. Teva, M.P. Oliveira-Neto, A.J. Silva, M.S. Pereira, and E. Cupolillo Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease Mem Inst Oswaldo Cruz 97 2002 1041 1048 (Pubitemid 135747502)
37. J.E. Uzonna, G. Wei, D. Yurkowski, and P. Bretscher Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease J Immunol 167 2001 6967 6974 (Pubitemid 33144191)
38. J.E. Uzonna, G.F. Spath, S.M. Beverley, and P. Scott Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response J Immunol 172 2004 3793 3797 (Pubitemid 38337964)
39. G.F. Spath, L.F. Lye, H. Segawa, D.L. Sacks, S.J. Turco, and S.M. Beverley Persistence without pathology in phosphoglycan deficient Leishmania major Science 301 2003 1241 1243 (Pubitemid 37052214)
40. C. Kebaier, J. Uzonna, S.M. Beverley, and P. Scott Immunization with persistent attenuated (delta) lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice Infect Immun 74 2006 777 780 (Pubitemid 43023138)
41. T. Ilg, M. Demar, and D. Harbecke Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice J Biol Chem 276 2001 4988 4997
42. G.F. Spath, L.F. Lye, H. Segawa, S.J. Turco, and S.M. Beverley Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies Infect Immun 72 2004 3622 3627 (Pubitemid 38697791)
43. J. Alexander, G.H. Coombs, and J.C. Mottram Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response J Immunol 161 1998 6794 6801 (Pubitemid 28562223)
44. N.G. Saravia, B. Escorcia, Y. Osorio, L. Valderrama, D. Brooks, and L. Arteaga Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models Vaccine 24 2006 4247 4259
45. R.J. Burchmore, D. Rodriguez-Contreras, K. McBride, P. Merkel, M.P. Barrett, and G. Modi Genetic characterization of glucose transporter function in Leishmania mexicana Proc Natl Acad Sci U S A 100 7 2003 3901 3906 (Pubitemid 36418129)
46. D. Rodriguez-Contreras, X. Feng, K.M. Keeney, H.G. Bouwer, and S.M. Landfear Phenotypic characterization of a glucose transporter null mutant in Leishmania mexicana Mol Biochem Parasitol 153 1 2007 9 18 (Pubitemid 46517669)
47. P.B. Joshi, D.L. Sacks, G. Modi, and W.R. McMaster Targeted gene deletion of Leishmania major genes encoding developmental stage-specific leishmanolysin (GP63) Mol Microbiol 27 1998 519 530 (Pubitemid 28045734)
48. P.B. Joshi, B.L. Kelly, S. Kamhawi, D.L. Sacks, and W.R. McMaster Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor Mol Biochem Parasitol 120 2002 33 40 (Pubitemid 34159290)
49. R. Silvestre, A. Cordeiro-da-Silva, N. Santarém, B. Vergnes, D. Sereno, and A. Ouaissi SIR2-deficient Leishmania infantum induces a defined IFN-γ/IL-10 pattern that correlates with protection J Immunol 179 2007 3161 3170
50. B. Papadopoulou, G. Roy, M. Breton, C. Kundig, C. Dumas, and I. Fillion Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination Infect Immun 70 2002 62 68 (Pubitemid 34028599)
51. A. Selvapandiyan, A. Debrabant, R. Duncan, J. Muller, P. Salotra, and G. Sreenivas Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania J Biol Chem 279 2004 25703 25710 (Pubitemid 38756834)
52. A. Selvapandiyan, R. Duncan, A. Debrabant, N. Lee, G. Sreenivas, and P. Salotra Genetically modified live attenuated parasites as vaccines for leishmaniasis Indian J Med Res 123 2006 455 466 (Pubitemid 43905582)
53. M. Breton, M.J. Tremblay, M. Ouellette, and B. Papadopoulou Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis Infect Immun 73 2005 6372 6382 (Pubitemid 41368798)
54. R. Sporri, and C. Reis e Sousa Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function Nat Immunol 6 2005 163 170 (Pubitemid 40268197)
55. K.E. Foulds, C.Y. Wu, and R.A. Seder Th1 memory: implications for vaccine development Immunol Rev 211 2006 58 66 (Pubitemid 43882961)
56. R. Silvestre, A. Cordeiro-da-Silva, and A. Ouaissi Live attenuated Leishmania vaccines: a potential strategic alternative Arch Immunol Ther Exp 56 2008 123 126
57. A. Muyombwe, M. Olivier, P. Harvie, M.G. Bergeron, M. Ouellette, and B. Papadopoulou Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene J Infect Dis 177 1 1998 188 195 (Pubitemid 28030451)
58. N. Davoudi, F. Mahboudi, M. Azizi, A. Adeli, and W.R. McMaster Introduction of three independent selection markers in Leishmania Iran Biomed J 7 2003 13 18 (Pubitemid 36666019)
59. N. Davoudi, C.A. Tate, C. Warburton, A. Murray, F. Mahboudi, and W.R. McMaster Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials Vaccine 23 2005 1170 1177 (Pubitemid 40052013)
60. S. Kumari, M. Samant, P. Khare, P. Misra, S. Dutta, and B.K. Kolli Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis Eur J Immunol 39 1 2009 178 191
61. W. Mayrink, C.A. Da Costa, and P.A. Magalhaes A field trial of a vaccine against American dermal leishmaniasis Trans R Soc Trop Med Hyg 73 4 1979 385 387 (Pubitemid 9240974)
62. W. Mayrink, P. Williams, and C.A. Da Costa An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil Ann Trop Med Parasitol 79 3 1985 259 269 (Pubitemid 15227241)
63. I.D. Velez, S. del Pilar Agudelo, M.P. Arbelaez, K. Gilchrist, S.M. Robledo, and J.A. Puerta Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial Trans R Soc Trop Med Hyg 94 6 2000 698 703
64. I.D. Velez, K. Gilchrist, M.P. Arbelaez, C.A. Rojas, J.A. Puerta, and C.M. Antunes Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia Trans R Soc Trop Med Hyg 99 8 2005 593 598 (Pubitemid 40823865)
65. R.X. Armijos, M.M. Weigel, M. Calvopina, A. Hidalgo, W. Cevallos, and J. Correa Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis Vaccine 22 2004 1320 1326 (Pubitemid 38296677)
66. C.E. Sharples, M.A. Shaw, M. Castes, J. Convit, and J.M. Blackwell Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens Vaccine 12 1994 1402 1412 (Pubitemid 24347927)
67. J. Convit, P.L. Castellanos, and A. Rondon Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis Lancet 1 8530 1987 401 405 (Pubitemid 17016578)
68. J. Convit, M. Ulrich, O. Zerpa, R. Borges, N. Aranzazu, and M. Valera Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99 Trans R Soc Trop Med Hyg 97 2003 469 472 (Pubitemid 39186036)
69. M. Cabrera, J.M. Blackwell, M. Castes, D. Trujillo, J. Convit, and M.A. Shaw Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients Parasite Immunol 22 2000 73 79 (Pubitemid 30098807)
70. J. Machado-Pinto, J. Pinto, C.A. da Costa, O. Genaro, M.J. Marques, and F. Modabber Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania amazonensis vaccine plus antimonial Int J Dermatol 41 2002 73 78 (Pubitemid 34552351)
71. R.X. Armijos, M.M. Weigel, H. Aviles, R. Maldonado, and J. Racines Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up J Infect Dis 177 5 1998 1352 1357 (Pubitemid 28194278)
72. R.X. Armijos, M.M. Weigel, L. Romero, V. Garcia, and J. Salazar Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last? J Infect Dis 187 12 2003 1959 1961 (Pubitemid 36724495)
73. S. Noazin, F. Modabber, A. Khamesipour, P.G. Smith, L.H. Moulton, and K. Nasseri First generation leishmaniasis vaccines: a review of field efficacy trials Vaccine 26 52 2008 6759 6767
74. J. Convit, M. Ulrich, M.A. Polegre, A. Avila, N. Rodriguez, and M.I. Mazzedo Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin: preliminary report Mem Inst Oswaldo Cruz 99 2004 57 62 (Pubitemid 38406266)
75. W. Mayrink, O. Genaro, J.C. Silva, R.T. da Costa, W.L. Tafuri, and V.P. Toledo Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs Mem Inst Oswaldo Cruz 91 6 1996 695 697
76. R.C. Giunchetti, R. Correa-Oliveira, O.A. Martins-Filho, A. Teixeira-Carvalho, B.M. Roatt, and R.D. de Oliveira Aguiar-Soares Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs Vaccine 25 44 2007 7674 7686 (Pubitemid 47538812)
77. R.C. Giunchetti, A.B. Reis, D. da Silveira-Lemos, O.A. Martins-Filho, R. Correa-Oliveira, and J. Bethony Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis Res Vet Sci 85 1 2008 106 112 (Pubitemid 351682301)
78. E.E. Zijlstra, A.M. El-Hassan, A. Ismael, and H.W. Ghalib Endemic kala-azar in Eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis Am J Trop Med Hyg 51 6 1994 826 836
79. A. Misra, A. Dube, B. Srivastava, P. Sharma, J.K. Srivastava, and J.C. Katiyar Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG Vaccine 19 25-26 2001 3485 3492 (Pubitemid 32710300)
80. E.G. Rhee, S. Mendez, J.A. Shah, C.Y. Wu, J.R. Kirman, and T.N. Turon Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection J Exp Med 195 12 2002 1565 1573 (Pubitemid 34666070)
81. J.K. Srivastava, A. Misra, P. Sharma, B. Srivastava, S. Naik, and A. Dube Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis Parasitology 127 2 2003 107 114 (Pubitemid 37056119)
82. M.Y. Michel, F.M. Fathy, E.H. Hegazy, E.D. Hussein, M.M. Eissa, and D.E. Said The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis J Egypt Soc Parasitol 36 1 2006 159 176
83. R. Nagill, R. Mahajan, M. Sharma, and S. Kaur Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis Parasitol Int 58 4 2009 359 366
84. A.Z. Momeni, T. Jalayer, M. Emamjomeh, A. Khamesipour, F. Zicker, and R.L. Ghassemi A randomised, double blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran Vaccine 17 1998 466 472
85. I. Sharifi, A.R. Fe Kri, M.R. Aflatonian, A. Khamesipour, A. Nadim, and M.R.A. Mousavi Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran Lancet 351 1998 1540 1544
86. E.A.G. Khalil, El Hassan, E.E. Zijlstra, M.M. Mukhtar, H.W. Ghalib, and B. Musa Autoclaved L major vaccine for prevention of visceral leishmaniasis: a randomised double-blind BCG-controlled trial in Sudan Lancet 356 2000 1565 1569
87. I.N. Satti, H.Y. Osman, N.S. Daifalla, S.A. Younis, E.A. Khalil, and E.E. Zijlstra Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers Vaccine 19 2001 2100 2106 (Pubitemid 32178360)
88. R.T. Kenney, D.L. Sacks, J.P. Sypek, L. Vilela, A.A. Gam, and K. Evans-Davis Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis J Immunol 163 1999 4481 4488 (Pubitemid 29474517)
89. M. Mohebali, A. Khamesipour, I. Mobedi, Z. Zarei, and R. Hashemi-Fesharki Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran Vaccine 22 2004 4097 4100 (Pubitemid 39208776)
90. A.A. Kamil, E.A.G. Khalil, A.M. Musa, F. Modabber, M.M. Mukhtar, and M.E. Ibrahim Alum precipitated autoclaved L major plus BCG a candidate vaccine for visceral leishmaniasis: safety skin delayed hypersensitivity response and dose finding in healthy volunteers Trans R Soc Trop Med Hyg 97 2003 365 368 (Pubitemid 39185899)
91. E.A. Khalil, A.M. Musa, F. Modabber, and A.M. El-Hassan Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study Ann Trop Paediatr 26 4 2006 357 361 (Pubitemid 47054674)
92. H. Ghalib, and F. Modabber Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis Kinetoplastid Biol Dis 6 2007 7 20
93. D.M. Yang, N. Fairweather, L.L. Button, W.R. McMaster, L.P. Kahl, and F.Y. Liew Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis J Immunol 145 1990 2281 2285 (Pubitemid 20343397)
94. Y.A. Skeiky, J.A. Guderian, D.R. Benson, O. Baceloar, E.M. Carvalho, and M. Kubin A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12 J Exp Med 181 1995 1527 1537
95. S. Gurunathan, D.L. Sacks, D.R. Brown, S.L. Reiner, H. Charest, and N. Glaichenhaus Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major J Exp Med 186 1997 1137 1147 (Pubitemid 27441157)
96. C.B. Palatnik de Sousa, R. Borojevic, J.O. Previato, and L. Mendonca-Previato Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate Infect Immun 57 1989 754 763 (Pubitemid 19064535)
97. A. Jardim, D.L. Tolson, S.J. Turco, T.W. Pearson, and R.W. Olafson The Leishmania donovani lipophosphoglycan T lymphocyte reactive component is a tightly associated protein complex J Immunol 147 1991 3538 3544
98. N. Rachamim, and C.L. Jaffe Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis J Immunol 150 1993 2322 2331 (Pubitemid 23127477)
99. E. Handman, L.F. Schnur, T.W. Spithill, and G.F. Mitchell Passive transfer of Leishmania lipopolysaccharide confers parasite survival in macrophages J Immunol 137 1986 3608 3613 (Pubitemid 17193324)
100. P.C. Melby, G.B. Ogden, H.A. Flores, W. Zhao, C. Geldmacher, and N.M. Biediger Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library Infect Immun 68 2000 5595 5602
101. S.G. Reed, R. Badaro, and R.M. Lloyd Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera J Immunol 138 1987 1596 1601 (Pubitemid 17029462)
102. J.M. Burns Jr., W.G. Shreffler, D.R. Benson, H.W. Ghalib, R. Badaro, and S.G. Reed Molecular characterization of a kinesin related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis Proc Natl Acad Sci U S A 90 2 1993 775 779 (Pubitemid 23028948)
103. Y.A. Skeiky, D.R. Benson, J.A. Guderian, J.A. Whittle, O. Bacelar, and E.M. Carvalho Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans Infect Immun 63 1995 4105 4114
104. J.R. Webb, A. Campos-Neto, Y.A.W. Skeiky, and S.G. Reed Molecular characterization of the heat inducible LmSTI1 protein of Leishmania major Mol Biochem Parasitol 89 1997 179 193 (Pubitemid 27435091)
105. J.R. Webb, D. Kaufmann, A. Campos-Neto, and S.G. Reed Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis J Immunol 157 11 1996 5034 5041 (Pubitemid 126449584)
106. Y.A.W. Skeiky, M. Kennedy, D. Kaufman, M.M. Borges, J.A. Guderian, and J.K. Scholler LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile J Immunol 161 11 1998 6171 6179 (Pubitemid 28535990)
107. S. Rafati, A.H. Salmanian, K. Hashemi, C. Schaff, S. Belli, and N. Fasel Identification of Leishmania major cysteine proteinases as targets of the immune response in humans Mol Biochem Parasitol 113 1 2001 35 43 (Pubitemid 32209280)
108. D. Rivier, P. Bovay, R. Shah, S. Didisheim, and J. Mauel Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection Parasite Immunol 21 1999 461 473 (Pubitemid 29401766)
109. E. Handman, L.L. Button, and W.R. McMaster Leishmania major: production of recombinant gp63 its antigenicity and immunogenicity in mice Exp Parasitol 70 4 1990 427 435 (Pubitemid 20230669)
110. J.O. Olobo, C.O. Anjili, M.M. Gicheru, P.A. Mbati, T.M. Kariuki, and J.I. Githure Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania major 'surface glycoprotein' (gp63) Vet Parasitol 60 3-4 1995 199 212
111. D.G. Russell, and J. Alexander Effective immunization cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes J Immunol 140 4 1988 1274 1279 (Pubitemid 18096704)
112. D. Xu, S.J. McSorley, S.N. Chatfield, G. Dougan, and F.Y. Liew Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-) Immunology 85 1995 1 7
113. S.J. McSorley, D. Xu, and F.Y. Liew Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters Infect Immun 65 1997 171 178 (Pubitemid 27008919)
114. C.R. Gonzalez, F.R. Noriega, S. Huerta, A. Santiago, M. Vega, and J. Paniagua Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana Vaccine 16 1998 1043 1052 (Pubitemid 28276021)
115. N.D. Connell, E. Medina-Acosta, W.R. McMaster, B.R. Bloom, and D.G. Russell Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63 Proc Natl Acad Sci U S A 15 1993 11473 11477 (Pubitemid 24008661)
116. S. Abdelhak, H. Louzir, J. Timm, L. Blel, Z. Benlasfar, and M. Lagranderie Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice Microbiology 141 1995 1585 1592
117. M.R. Jaafari, A. Ghafarian, A. Farrokh-Gisour, A. Samiei, M.T. Kheiri, and F. Mahboudi Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice Vaccine 24 29-30 2006 5708 5717 (Pubitemid 43928184)
118. S. Bhowmick, R. Ravindran, and N. Ali gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani Infect Immun 76 3 2008 1003 1015 (Pubitemid 351428060)
119. C.L. Jaffe, N. Rachamim, and R. Sarfstein Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis J Immunol 144 2 1990 699 706 (Pubitemid 20036105)
120. M. Kemp, T.G. Theander, E. Handman, A.S. Hey, J.A. Kurtzhals, and L. Hviid Activation of human T lymphocytes by Leishmania lipophosphoglycan Scand J Immunol 33 1991 219 224
121. S.C. Mendonca, D.G. Russell, and S.G. Coutinho Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63) Clin Exp Immunol 83 1991 472 478
122. D.M. Russo, J.M. Burns Jr., E.M. Carvalho, R.J. Armitage, K.H. Grabstein, and L.L. Button Human T-cell responses to gp63 a surface antigen of Leishmania J Immunol 147 1991 3575 3580
123. A. Jardim, J. Alexander, H.S. Teh, D. Ou, and R.W. Olafson Immunoprotective Leishmania major synthetic T cell epitopes J Exp Med 172 2 1990 645 648 (Pubitemid 20248406)
124. N. Spitzer, A. Jardim, D. Lippert, and R.W. Olafson Long-term protection of mice against Leishmania major with a synthetic peptide vaccine Vaccine 17 1999 1298 1300 (Pubitemid 29138794)
125. C. Berberich, J.R. Ramirez-Pineda, C. Hambrecht, G. Alber, Y.A. Skeiky, and H. Moll Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens J Immunol 170 2003 3171 3179 (Pubitemid 36302194)
126. P. Tsagozis, E. Karagouni, and E. Dotsika Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis Int J Immunopathol Pharmacol 17 2004 343 352 (Pubitemid 39481677)
127. G. Chen, P.A. Darrah, and D.M. Mosser Vaccination against the intracellular pathogens Leishmania major and L amazonensis by directing CD40 ligand to macrophages Infect Immun 69 2001 3255 3263 (Pubitemid 32332224)
128. K.L. Lohman, P.J. Langer, and D. McMahon-Pratt Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis Proc Natl Acad Sci U S A 87 21 1990 8393 8397
129. L.P. Kahl, and D. McMahon-Pratt Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein J Immunol 138 5 1987 1587 1595 (Pubitemid 17029461)
130. D. McMahon-Pratt, Y. Traub-Cseko, K.L. Lohman, D.D. Rogers, and S.M. Beverley Loss of the GP46/M2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex Mol Biochem Parasitol 50 1992 151 160
131. F.M. Symons, P.J. Murray, H. Ji, R.J. Simpson, A.H. Osborn, and R. Cappai Characterization of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species Mol Biochem Parasitol 67 1994 103 113 (Pubitemid 24287315)
132. J. Champsi, and D. McMahon-Pratt Membrane glycoprotein M-2 protects against Leishmania amazonensis infection Infect Immun 56 1988 3272 3279
133. D. McMahon-Pratt, D. Rodriguez, J.-R. Rodriguez, Y. Zhang, K. Manson, and C. Bergman Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection Infect Immun 61 8 1993 3351 3359 (Pubitemid 23223426)
134. W.K. Tonui, J.S. Mejja, L. Hochberg, M.L. Mbow, J.R. Ryan, and A.S.T. Chen Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L major Infect Immun 72 10 2004 5654 5661 (Pubitemid 39303674)
135. L. Kedzierski, J. Montgomery, D. Bullen, J. Curtis, E. Gardiner, and A. Jimenez-Ruiz A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3 J Immunol 172 2004 4902 4906 (Pubitemid 38456414)
136. P.J. Murray, and T.W. Spithill Variants of a Leishmania surface antigen derived from a multigenic family J Biol Chem 266 1991 24477 24484 (Pubitemid 21908965)
137. E. Handman, F.M. Symons, T.M. Baldwin, J.M. Curtis, and J.P.Y. Scheerlinck Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response Infect Immun 63 11 1995 4261 4267
138. A. Sjolander, T.M. Baldwin, J.M. Curtis, K.L. Bengtsson, and E. Handman Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection Vaccine 16 20 1998 2077 2084 (Pubitemid 28473959)
139. M. Kemp, E. Handman, K. Kemp, A. Ismail, M.D. Mustafa, and A.Y. Kordofani The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major FEMS Immunol Med Microbiol 20 3 1998 209 218 (Pubitemid 28172699)
140. E. Mougneau, F. Altare, A.E. Wakil, S. Zheng, T. Coppala, and Z.E. Wang Expression cloning of a protective Leishmania antigen Science 268 1995 563 566
141. G. Gonzalez-Aseguinolaza, S. Taladriz, A. Marquet, and V. Larraga Molecular cloning cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum Eur J Biochem 259 1999 909 916 (Pubitemid 29075523)
142. V. Julia, M. Rassoulzadegan, and N. Glaichenhaus Resistance to Leishmania major induced by tolerance to a single antigen Science 274 1996 421 423 (Pubitemid 26353355)
143. P. Launois, I. Maillard, S. Pingel, K.G. Swihart, I. Xenarios, and H. Acha-Orbea IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice Immunity 6 1997 541 549 (Pubitemid 27239345)
144. S. Gurunathan, C. Prussin, D.L. Sacks, and R.A. Seder Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection Nat Med 4 1998 1409 1415 (Pubitemid 28553464)
145. E.A. Ferraz Coelho, C.A. Pereira Tavares, F.A. Amorim Carvalho, K.F. Chaves, K.N. Teixeira, and R.C. Rodriguez Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen but not by the LACK antigen are protective against experimental Leishmania (Leishmania) amazonensis infection Infect Immun 71 7 2003 3988 3994 (Pubitemid 36753724)
146. E.F. Pinto, R.O. Pinheiro, A. Rayol, V. Larraga, and B. Rossi-Bergmann Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK Infect Immun 72 2004 4521 4527 (Pubitemid 38989310)
147. E. Bourreau, G. Prevot, J. Gardon, R. Pradinaud, H. Hasagewa, and G. Milon LACK-specific CD4+ T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection Infect Immun 70 6 2002 3122 3129 (Pubitemid 34564175)
148. K. Maasho, I. Satti, S. Nylen, G. Guzman, F. Koning, and H. Akuffo A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-γ and interleukin-10 in natural killer cells of healthy blood donors J Infect Dis 182 2 2000 570 578 (Pubitemid 30651056)
149. E. Bourreau, M. Collet, G. Prevot, G. Milon, D. Ashimoff, and H. Hasagewa IFN-γ-producing CD45RA+ CD8+ and IL-10-producing CD45RA- CD4+ T cells generated in response to LACK in naive subjects never exposed to Leishmania Eur J Immunol 32 2 2002 510 520 (Pubitemid 34176770)
150. L.P. Carvalho, S. Passos, W.O. Dutra, M. Soto, C. Alonso, and K.J. Gollob Effect of LACK and KMP11 on IFN-γ production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients Scand J Immunol 61 4 2005 337 342 (Pubitemid 40637838)
151. L.E. Parra, G.P. Borja-Cabrera, F.N. Santos, and L.O.P. Souza Palatnik de Sousa CB, Menz I. Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil Vaccine 25 12 2007 2180 2186 (Pubitemid 46242143)
152. C.B. Palatnik de Sousa, H.S. Dutra, and R. Borojevic Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML) Acta Trop 53 1 1993 59 72 (Pubitemid 23113698)
153. C.B. Palatnik de Sousa, E. Paraguai de Souza, E.M. Gomes, and R. Borojevic Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML) Braz J Med Biol Res 27 2 1994 547 551
154. W.R. Santos, I.A. Aguiar, E.P. De Sousa, V.M.F. De Lima, M. Palatnik, and C.B. Palatnik de Sousa Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine Vaccine 21 32 2003 4668 4676 (Pubitemid 37336560)
155. C.B. Palatnik de Sousa, E.M. Gomes, E. Paraguai de Souza, W.R. Dos Sontis, S.R. De Macedo, and L.V. De Medeiros The FML (Fucose Mannose Ligand) of Leishmania donovani. A new tool in diagnosis prognosis transfusional control and vaccination against human kala-azar Rev Soc Bras Med Trop 29 2 1996 153 163 (Pubitemid 26109376)
156. W.R. Santos, E. Paraguai de Souza, M. Palatnik, and C.B. Palatnik de Sousa Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani Vaccine 17 1999 2554 2561 (Pubitemid 29314448)
157. C.B. Palatnik de Sousa, M.B. Moreno, E. Paraguai de Souza, and R. Borojevic The FML vaccine (fucose-mannose ligand) protects hamsters from experimental kala-azar Ciencia e Cultura J Braz Assoc Adv Sci 46 1994 290 296
158. W.R. Santos, V.M.F. De Lima, E.P. De Sousa, R.R. Bernardo, M. Palatnik, and C.B.P. de Sousa Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis Vaccine 21 1-2 2002 30 43 (Pubitemid 35355720)
159. E. Oliveira-Freitas, C.P. Casas, G.P. Borja-Cabrera, F.N. Santos, D. Nico, and L.O.P. Souza Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis Vaccine 24 18 2006 3909 3920
160. E. Paraguai de Souza, R.R. Bernardo, M. Palatnik, and C.B. Palatnik de Sousa Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani Vaccine 19 23-24 2001 3104 3115 (Pubitemid 32324038)
161. V.O. da Silva, G.P. Borja-Cabrera, N.N. Correia Pontes, E. Paraguai de Souza, K.G. Luz, and M. Palatnik A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto RN) Vaccine 19 9-10 2000 1082 1092 (Pubitemid 32008272)
162. G.P. Borja-Cabrera, N.N. Correia Pontes, V.O. De Silva, E. Paraguai De Souza, W.R. Santos, and E.M. Gomes Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante RN) Vaccine 20 27-28 2002 3277 3284 (Pubitemid 35251815)
163. G.P. Borja-Cabrera, A.C. Mendes, E. Paraguai De Souza, L.Y.H. Okada, F.A.D.A. Trivellato, and J.K.A. Kawasaki Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Vaccine 22 17-18 2004 2234 2243 (Pubitemid 38656119)
164. F.N. Santos, G.P. Borja-Cabrera, L.M. Miyashiro, J. Grechi, A.B. Reis, and M.A.B. Moreira Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine Vaccine 25 33 2007 6176 6190 (Pubitemid 47090200)
165. G.P. Borja-Cabrera, F.N. Santos, F.S. Bauer, L.E. Parra, I. Menz, and A.A. Morgado Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil Vaccine 26 39 2008 4991 4997
166. C.B. Palatnik de Sousa, A.D.F. Barbosa, S.M. Oliveira, D. Nico, R.R. Bernardo, and W.R. Santos FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine Expert Rev Vaccines 7 6 2008 833 851
167. M.S.S. Araujo, R.A. de Andrade, L.R. Vianna, W. Mayrink, A.B. Reis, and R. Sathler Avelar Despite Leishvaccine and Leishmune® trigger distinct immune profiles their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis Vaccine 26 18 2008 2211 2224
168. M.S.S. Araujo, R.A. de Andrade, R. Sathler Avelar, A. Teixeira-Carvalho, M.C. Andrade, and L.R. Vianna T-cell-derived cytokines nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune Vaccine 27 7 2009 1008 1017
169. F.S. Nogueira, M.A.B. Moreira, G.P. Borja Cabrera, F.N. Santos, I. Menz, and L.E. Parra Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood skin and lymph nodes of vaccinated exposed dogs Vaccine 23 40 2005 4805 4810 (Pubitemid 41242874)
170. E.M. Saraiva, A.D.F. Barbosa, F.N. Santos, G.P. Borjo-Cabrera, D. Nico, and L.O.P. Souza The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine Vaccine 24 13 2006 2423 2431 (Pubitemid 43290426)
171. F. Dantas-Torres Leishmune® vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine Vet Parasitol 141 1-2 2006 1 8 (Pubitemid 44363138)
172. G.P. Borja-Cabrera, V.O. da Silva, R.T. Da Costa, A.B. Reis, W. Mayrink, and O. Genaro The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil Am J Trop Med Hyg 61 2 1999 296 301 (Pubitemid 29380265)
173. C.B. Palatnik de Sousa, E.M. Gomes, E. Paraguai-de-Sousa, M. Palatnik, K. Luz, and R. Borojevic Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis Trans R Soc Trop Med Hyg 89 4 1995 390 393
174. J.L. Lemesre, P. Holzmuller, M. Cavaleyra, R.B. Goncalves, G. Hottin, and G. Papierok Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes Vaccine 23 2005 2825 2840 (Pubitemid 40386484)
175. J.L. Lemesre, P. Holzmuller, R.B. Goncalves, G. Bourdoiseau, C. Hugnet, and M. Cavaleyra Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial Vaccine 25 21 2007 4223 4234 (Pubitemid 46661824)
176. G. Bourdoiseau, C. Hugnet, R.B. Goncalves, F. Vezilier, E. Petit-Didier, and G. Papierok Effective humoral and cellular immunoprotective responses in LiESAp-MDP vaccinated protected dogs Vet Immunol Immunopathol 128 1-3 2009 71 78
177. P. Holzmuller, M. Cavaleyra, J. Moreaux, R. Kovacic, P. Vincendeau, and G. Papierok Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis Vet Immunol Immunopathol 106 3-4 2005 247 257 (Pubitemid 40814374)
178. S. Rafati, N. Fasel, and S. Masina Leishmania cysteine proteinases: from gene to subunit vaccine Curr Genom 4 3 2003 253 261 (Pubitemid 36348202)
179. J. McKerrow, J. Engel, and C. Caffrey Cysteine protease inhibitors as chemotherapy for parasitic infections Bioorg Med Chem 7 1999 639 644 (Pubitemid 29150307)
180. C.D. Robertson, G.H. Coombs, M.J. North, and J.C. Mottram Parasite cysteine proteinases Perspect Drug Discov 6 1996 99 118 (Pubitemid 126484498)
181. T. Aebischer, M. Wolfram, S.I. Patzer, T. IIg, M. Wiese, and P. Overath Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants Infect Immun 68 3 2000 1328 1336 (Pubitemid 30108529)
182. S. Rafati, A. Abraham Baba, M. Bakhshayesh, and M. Vafa Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase Clin Exp Immunol 120 2000 134 138 (Pubitemid 30176910)
183. S. Rafati, A. Kariminia, S. Seyde-Eslami, M. Narimani, T. Taheri, and M. Lebbatard Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation Vaccine 20 2002 2439 2447 (Pubitemid 34615581)
184. A. Zadeh-Vakili, T. Taheri, Y. Taslimi, F. Doustdari, A.-H. Salmanian, and S. Rafati Immunization with the hybrid protein vaccine consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA) partially protects against leishmaniasis Vaccine 22 16 2004 1930 1940 (Pubitemid 38581062)
185. H. Pascalis, A. Lavergne, E. Bourreau, G. Prevot-Linguet, A. Kariminia, and R. Pradinaud Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis Infect Immun 71 5 2003 2924 2926 (Pubitemid 36519911)
186. S. Rafati, A. Nakhaee, T. Taheri, A. Ghashghaii, A.-H. Salmanian, and M. Jimenez Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis Exp Parasitol 103 3-4 2003 143 151 (Pubitemid 36918189)
187. S. Rafati, S. Couty-Jouve, M.H. Alimohammadian, and J.A. Louis Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis Clin Exp Immunol 110 2 1997 203 211 (Pubitemid 27469592)
188. P.H. da Costa Pinheiro, Dias S. De Souza, K. Dantas Eulalio, I.L. Mendonca, S. Katz, and C.L. Barbieri Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses Infect Immun 73 6 2005 3787 3789 (Pubitemid 40745928)
189. C.R. Alves, T.C. Benevolo-De-Andrade, J.L. Alves, and C. Pirmez Th1 and Th2 immunological profile induced by cysteine proteinase in murine leishmaniasis Parasite Immunol 26 3 2004 127 135 (Pubitemid 39070684)
190. J.H.L. Ferreira, L.G. Gentil, S.S. Dias, C.E.C. Fedeli, S. Katz, and C.L. Barbieri Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis Vaccine 26 5 2008 677 685
191. H.R.B. Pehlam Speculations on the functions of the major heat shock and glucose-regulated proteins Cell 46 1986 959 961
192. K. Normington, K. Kohno, Y. Kozutsumi, M.J. Gething, and J. Sambrook S. cerevisiae encodes an essential protein homologous in sequence and function to mammalian BiP Cell 57 1989 1223 1236 (Pubitemid 19169818)
193. M. Rose, L.M. Misra, and J.P. Vogel KAR2 a karyogamy gene is a yeast homolog of mammalian BiP/grp78 Cell 57 1989 1211 1221 (Pubitemid 19169817)
194. R.S. Tibbetts, I.Y. Kim, C.L. Olson, L.M. Barthel, M.A. Sullivan, and A.G. Winquist Molecular cloning and characterization of the 78-kilodalton glucose-regulated protein of Trypanosoma cruzi Infect Immunol 62 1994 2499 2507 (Pubitemid 24157082)
195. A.C. Ivens, C.S. Peacock, E.A. Worthey, L. Murphy, G. Aggarwal, and M. Berriman The genome of the kinetoplastid parasite Leishmania major Science 309 5733 2005 436 442 (Pubitemid 40994677)
196. Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al. Analysis of genome architecture and content between three Leishmania species causing diverse human disease reveals only a small subset of species-specific genes (Unpublished data).
197. C.S. Peacock, K. Seeger, D. Harris, L. Murphy, J.C. Ruiz, and M.A. Quail Comparative genomic analysis of three Leishmania species that cause diverse human disease Nat Genet 39 7 2007 839 847 (Pubitemid 47014491)
198. A.T.R. Jensen, J. Curtis, J. Montgomery, E. Handman, and T.G. Theander Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani Biochim Biophys Acta 1549 1 2001 73 87 (Pubitemid 32879350)
199. M. Mukherjee, A. Bhattacharyya, and S. Duttagupta Serodiagnostic and immunoprophylactic potential of a 78 kDa protein of Leishmania donovani of Indian origin Med Sci Monit 8 4 2002 BR117 BR122
200. R. Nagill, and S. Kaur Enhanced efficacy and immunogenicity of 78 kDa antigen formulated in various adjuvants against murine visceral leishmaniasis Vaccine 28 2010 4002 4012
201. L. Soong, S.M. Duboise, P. Kima, and D. McMahon-Pratt Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis Infect Immun 63 9 1995 3559 3566
202. S.M. Whitaker, M. Colmenares, K.G. Pestana, and D. McMahon-Pratt Leishmania pifanoi proteoglycolipid complex P8 induces macrophage cytokine production through Toll-like receptor 4 Infect Immun 76 5 2008 2149 2156 (Pubitemid 351656149)
203. S. Kar, C. Metz, and D. McMahon-Pratt CD4+ T cells play a dominant role in protection against new world leishmaniasis induced by vaccination with the P-4 amastigote antigen Infect Immun 73 6 2005 3823 3827 (Pubitemid 40745937)
204. E. Carrillo, S. Ahmed, K. Goldsmith-Pestana, J. Nieto, Y. Osorio, B. Travi, J. Moreno, and D. McMahon-Pratt Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis Vaccine 25 8 2007 1534 1543 (Pubitemid 46074295)
205. S.G. Coutinho, M.P. Oliveira, A.M. Da-Cruz, P.M. De Luca, S.C.F. Mendonca, and A.L. Bertho T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure Exp Parasitol 84 2 1996 144 155
206. F.T. Silveira, J.M. Blackwell, E.A. Ishikawa, R. Braga, J.J. Shaw, and R.J. Quinnell T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia Parasite Immunol 20 1 1998 19 26 (Pubitemid 28186281)
207. J.E. Haberer, A.M. Da-Curz, L. Soong, M.P. Oliveira-Neto, L. Rivas, and D. McMahon-Pratt Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis Infect Immun 66 7 1998 3100 3105 (Pubitemid 28303103)
208. S. Kar, L. Soong, M. Colmenares, K. Goldsmith-Pestana, and D. McMahon-Pratt The immunologically protective P-4 antigen of Leishmania amastigotes: a developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum J Biol Chem 275 48 2000 37789 37797 (Pubitemid 32004895)
209. A. Ghosh, W.W. Zhang, and G. Matlashewski Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections Vaccine 20 2001 59 66 (Pubitemid 32905314)
210. D.M. Resende, B.C. Caetano, M.S. Dutra, M.L.O. Penido, C.F. Abrantes, and R.M. Verly Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-γ and cytolytic activity by CD8+ T cells Vaccine 26 35 2008 4585 4593
211. A.P. Fernandes, M.M.S. Costa, E.A.F. Coelho, M.S.M. Michalick, E. de Freitas, and M.N. Melo Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein Vaccine 26 46 2008 5888 5895
212. S. Stager, D.F. Smith, and P.M. Kaye Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis J Immunol 165 2000 7064 7071 (Pubitemid 32001180)
213. J. Moreno, J. Nieto, S. Masina, E. Carrillo, C. Canavate, and I. Cruz Immunization with H1 and HASPB1 Leishmania proteins protect dogs against experimental canine leishmaniasis Proceedings of the Third World Congress on Leishmaniosis Palermo-Terrasini (Italy) 2005 178 213
214. J. Moreno, J. Nieto, S. Masina, C. Canavate, I. Cruz, and C. Chicharro Immunization with H1 HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis Vaccine 25 29 2007 5290 5300 (Pubitemid 46977538)
215. M.E. Wilson, B.M. Young, K.P. Anderson, J.V. Weinstock, A. Metwali, and K.M. Ali A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice Infect Immun 63 1995 2062 2069
216. J.A. Streit, J.E. Oonelson, and M.E. Wilson A recombinant bcg vaccine expressing the Leishmania chagasi antigen lcr1 J Invest Med 44 3 1996 320a (Pubitemid 126818000)
217. J.A. Streit, T.J. Recker, J.E. Donelson, and M.E. Wilson BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice Exp Parasitol 94 1 2000 33 41 (Pubitemid 30062518)
218. S. Masina, M.M. Gicheru, S.O. Demotz, and N.J. Fasel Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen J Infect Dis 188 8 2003 1250 1257 (Pubitemid 37338991)
219. N. Solioz, U. Blum-Tirouvanziam, R. Jacquet, S. Rafati, G. Corradin, and J. Mauel The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis Vaccine 18 1999 850 859
220. A. Ghosh, R. Madhubala, P.J. Myler, and K.D. Stuart Leishmania donovani: characterization and expression of ORFF a gene amplified from the LDI locus Exp Parasitol 93 4 1999 225 230
221. M. Jain, and R. Madhubala Characterization and localization of ORFF gene from the LD1 locus of Leishmania donovani Gene 416 1-2 2008 1 10
222. V.S. Dole, V.S. Raj, A. Ghosh, R. Madhubala, P.J. Myler, and K.D. Stuart Immunization with recombinant LD1 antigens protects against experimental leishmaniasis Vaccine 19 2000 423 430
223. P. Tewary, B. Sukumaran, S. Saxena, and R. Madhubala Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen Vaccine 22 23-24 2004 3053 3060 (Pubitemid 39037207)
224. P. Tewary, M. Jain, M.H. Sahani, S. Saxena, and R. Madhubala A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis J Infect Dis 191 12 2005 2130 2137 (Pubitemid 40800585)
225. P. Tewary, S. Saxena, and R. Madhubala Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis Vaccine 24 13 2006 2409 2416 (Pubitemid 43290424)
226. C.L. Jaffe, and M. Zalis Use of purified parasite proteins from Leishmania donovani for the rapid serodiagnosis of visceral leishmaniasis J Infect Dis 157 6 1988 1212 1220
227. M. Soto, J.M. Requena, L. Quijada, F. Guzman, M.E. Patarroyo, and C. Alonso Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis Immunol Lett 48 1 1995 23 28 (Pubitemid 26011516)
228. S. Iborra, J. Carrion, C. Anderson, C. Alonso, D. Sacks, and M. Soto Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice Infect Immun 73 9 2005 5842 5852 (Pubitemid 41193021)
229. S. Iborra, N. Parody, D.R. Abanades, P. Bonay, D. Prates, F.O. Novais, M. Barral-Netto, C. Alonso, and M. Soto Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice Microbes Infect 10 10-11 2008 1133 1141
230. D.L. Tolson, A. Jardim, L.F. Schnur, C. Stebeck, C. Tuckey, R.P. Beecroft, H.-S. Teh, R.W. Olafson, and T.W. Pearson The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation Infect Immun 62 11 1994 4893 4899 (Pubitemid 24332793)
231. C. Trujillo, R. Ramirez, I.D. Velez, and C. Berberich The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes Immunol Lett 70 3 2000 203 209 (Pubitemid 29537699)
232. V. Iniesta, I. Corraliza, J. Carcelen, L. Gomez Gordo, J. Fernandez-Cotrina, and J.C. Parejo Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite Parasitol Res 102 5 2008 887 893
233. A.T.R. Jensen, S. Gasim, A. Ismail, A. Gaafar, J.A.L. Kurtzhals, and M. Kemp Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11 Scand J Immunol 48 1 1998 103 109 (Pubitemid 28329160)
234. E. Carrillo, M. Crusata, J. Nietoa, C. Chicharroa, M.C. Thomas, and E. MartInez Immunogenicity of HSP-70 KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis Vaccine 26 2008 1902 1911
235. J.R. Ramirez, K. Gilchrist, S. Robledo, J.C. Sepulveda, H. Moll, and D. Soldati Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice Vaccine 20 3-4 2001 455 461 (Pubitemid 32973788)
236. R. Basu, S. Bhaumik, A.K. Haldar, K. Naskar, T. De, and S.K. Dana Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13 Infect Immun 75 12 2007 5956 5966 (Pubitemid 350207836)
237. N.G. Saravia, M.H. Hazbon, Y. Osorio, L. Valderrama, J. Walker, and C. Santrich Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana Vaccine 23 8 2005 984 995 (Pubitemid 40037647)
238. S.K. Gupta, B.S. Sisodia, S. Sinha, K. Hajela, S. Naik, and A.K. Shasany Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes Proteomics 7 5 2007 816 823 (Pubitemid 46450658)
239. S. Kumari, M. Samant, P. Khare, S. Sunder, S. Sinha, and A. Dube Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa Vaccine 26 37 2008 4813 4818
240. S. Kumari, M. Samant, P. Misra, P. Khare, B. Sisodia, and A.K. Shasany Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis Vaccine 26 45 2008 5700 5711
241. I. Molano, M.G. Alonso, C. Miron, E. Redondo, J.M. Requena, and M. Soto A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L infantum Vet Immunol Immunopathol 92 2003 1 13 (Pubitemid 36298678)
242. N. Parody, M. Soto, J.M. Requena, and C. Alonso Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum A CpG + Q mix protects Balb/c mice from infection Parasite Immunol 26 6-7 2004 283 293 (Pubitemid 39576329)
243. J.R. Webb, A. Campos-Neto, P.J. Oendale, T.I. Martin, E.J. Stromberg, and R. Badaro Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family Infect Immun 66 1998 3279 3289 (Pubitemid 28303127)
244. M.M. Borges, A. Campos-Neto, P. Sleath, K.H. Grabstein, P.J. Morrissey, and Y.A.W. Skeiky Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein Infect Immun 69 9 2001 5270 5277 (Pubitemid 32786457)
245. A. Campos-Neto, R. Porrozzi, K. Greeson, R.N. Coler, J.R. Webb, and Y.A.W. Seiky Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease Infect Immun 69 6 2001 4103 4108 (Pubitemid 32493335)
246. A. Badiee, M.R. Jaafari, and A. Khamesipour Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes Exp Parasitol 115 2 2007 127 134 (Pubitemid 44820050)
247. A. Badiee, M.R. Jaafari, A. Samiei, D. Soroush, and A. Khamesipour Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice Clin Vaccine Immunol 15 4 2008 668 674 (Pubitemid 351967047)
248. R.N. Coler, Y.A. Skeiky, K. Bernards, K. Greeson, D. Carter, and C.D. Cornellison Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant Leishmania major stress-inducible protein 1 and Leishmania elongation initiation factor protects against leishmaniasis Infect Immun 70 8 2002 4215 4225 (Pubitemid 34790930)
249. Y.A.W. Skeiky, R.N. Coler, M. Brannon, E. Stromberg, K. Greeson, and R. Thomas Crane Protective efficacy of a tandemly linked multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant Vaccine 20 27-28 2002 3292 3303 (Pubitemid 35245813)
250. R.N. Coler, Y. Goto, L. Bogatzki, V. Raman, and S.G. Reed Leish-111f a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells Infect Immun 75 9 2007 4648 4654 (Pubitemid 47378126)
251. R. Badaro, I. Lobo, A. Munos, E.M. Netto, F. Modabber, and A. Campos-Neto Immunotherapy for drug-refractory mucosal leishmaniasis J Infect Dis 194 8 2006 1151 1159 (Pubitemid 44547656)
252. G. Salay, M.L. Dorta, N.M. Santos, R.A. Mortara, C. Brodskyn, and C.I. Oliveira Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis the main causative agent of cutaneous leishmaniasis in the New World Clin Vaccine Immunol 14 9 2007 1173 1181 (Pubitemid 47518084)
253. R.T. Fujiwara, A.M. Vale, Franca da Silva JC, R.T. da Costa, S. Quetz Jda, and O.A. Martins Filho Immunogenicity in dogs of three recombinant antigens (TSA LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis Vet Res 36 5-6 2005 827 838 (Pubitemid 41323266)
254. L. Gradoni, V. Foglia Manzillo, A. Pagano, D. Piantedosi, R. De Luna, and M. Gramiccia Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals Vaccine 23 45 2005 5245 5251 (Pubitemid 41443430)
255. J. Miret, E. Nascimento, W. Sampaio, J.C. Franca, R.T. Fujiwara, and A. Vale Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis Vaccine 26 12 2008 1585 1594
256. M.A. Liu, B. Wahren, and G.B.K. Hedestam DNA vaccines: recent developments and future possibilities Hum Gene Ther 17 11 2006 1051 1061 (Pubitemid 44749708)
257. J.B. Alarcon, G.W. Waine, and D.P. McManus DNA vaccines: technology and application as anti-parasite and anti-microbial agents Adv Parasitol 42 1999 343 410
258. N.P. Restifo, H. Ying, L. Hwang, and W.W. Leitner The promise of nucleic acid vaccines Gene Ther 7 2000 89 92 (Pubitemid 30088954)
259. D. Xu, and F.Y. Liew Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein gp63 of L major Immunology 84 1995 173 176
260. K. Fragaki, I. Suffia, B. Ferrua, D. Rousseau, Y. Le Fichoux, and J. Kubar Immunization with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters Vaccine 19 2001 1701 1709 (Pubitemid 32175731)
261. S. Rafati, A.H. Salmanian, T. Taheri, M. Vafa, and N. Fasel A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major Vaccine 19 2001 3369 3375 (Pubitemid 32710285)
262. A. Campos-Neto, J.R. Webb, K. Greeson, R.N. Coler, Y.A. Skeiky, and S.G. Reed Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice Infect Immun 70 2002 2828 2836 (Pubitemid 34564138)
263. S.B.H. Ahmed, C. Bahloul, C. Robbana, S. Askri, and K. Dellagi A comparative evaluation of different DNA vaccine candidates against experimental murine due to L major Vaccine 22 13-14 2004 1631 1639 (Pubitemid 38447210)
264. S. Iborra, M. Soto, J. Carrion, C. Alonso, and J.M. Requena Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis Vaccine 22 29-30 2004 3865 3876 (Pubitemid 39208748)
265. I. Aguilar-Be, R.S. Zardo, E. Paraguai de Souza, G.P. Borja-Cabrera, M. Rosado-Vallado, and M. Mut-Martin Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis Infect Immun 73 2 2005 812 819 (Pubitemid 40165737)
266. A. Rodriguez-Cortes, A. Ojeda, L. Lopez-Fuertes, M. Timon, L. Altet, and L. Solano-Gallego Vaccination with plasmid DNA encoding KMPII TRYP LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge Vaccine 25 46 2007 7962 7971 (Pubitemid 47632977)
267. B. Sukumaran, P. Tewary, S. Saxena, and R. Madhubala Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani Vaccine 21 2003 1292 1299 (Pubitemid 36139962)
268. G.P. Borja-Cabrera, F.N. Santos, L.M. Miyashiro, F.B. Santos, and C.B. Palatnik de Sousa Nucleoside hydrolase DNA vaccine against visceral leishmaniasis. Vaccine Congress Celebrating 25 years of publication, 9-11 December 2007, the Netherlands, vol 1 2007 167
269. K. Campbell, H. Diao, J. Ji, and L. Soong DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis Infect Immun 71 2003 6270 6278 (Pubitemid 37337684)
270. R.M. Gonzalo, G. del Real, J.R. Rodriguez, D. Rodriguez, R. Heljasvaara, and P. Lucas A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis Vaccine 20 7-8 2002 1226 1231 (Pubitemid 34135960)
271. H. McShane Prime-boost immunization strategies for infectious diseases Curr Opin Mol Ther 4 1 2002 23 27 (Pubitemid 34649789)
272. M.J. Ramiro, J.J. Zarate, T. Hanke, D. Rodriguez, J.R. Rodriguez, and M. Esteban Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK Vaccine 21 19-20 2003 2474 2484 (Pubitemid 36561339)
273. L.O.P. Souza, and C.B. Palatnik-de-Sousa Cross-protective efficacy of the prophylactic VR1012-NH36 Leishmania donovani DNA vaccine against cutaneous leishmaniasis by Leishmania amazonensis. Abstracts of the Vaccine Congress: 25 years of publication, 9-11 December 2007, Amsterdam, the Netherlands, vol 1 2007 168
274. R. Basu, S. Bhaumik, J.M. Basu, K. Naskar, T. De, and S. Roy Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis J Immunol 174 11 2005 7160 7171 (Pubitemid 40705683)
275. S. Rafati, A. Nakhaee, T. Taheri, Y. Taslimi, H. Darabi, and D. Eravani Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and Type II of L infantum Vaccine 23 2005 3716 3725 (Pubitemid 40692418)
276. D. Xu, and F.Y. Liew Genetic vaccination against leishmaniasis Vaccine 12 1994 1534 1536 (Pubitemid 24360569)
277. P.S. Walker, T. Scharton-Kersten, E.D. Rowton, U. Hengge, A. Bouloc, and M.C. Udey Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis Hum Gene Ther 9 13 1998 1899 1907 (Pubitemid 28439095)
278. E. Dumonteil, F. Andrade-Narvarez, J. Escobedo-Ortegon, M.J. Ramirez-Sierra, G. Valencia-Pacheco, and A. Flores-Serrano Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana Dev Boil 104 2000 135 141
279. E. Dumonteil, R.-S.M. Jesus, E.-O. Javier, and G.M.M. Del Rosario DNA vaccines induce partial protection against Leishmania mexicana Vaccine 21 17-18 2003 2170 2177 (Pubitemid 36428806)
280. M. Rosado-Vallado, M. Mut-Martin, M. Del Rosario Garcia-Miss, and E. Dumonteil Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana Vaccine 23 46-47 2005 5372 5379 (Pubitemid 41579308)
281. A. Sjolander, T.M. Baldwin, J.M. Curtis, and E. Handman Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis J Immunol 160 8 1998 3949 3957 (Pubitemid 28176102)
282. E. Handman, A.H. Noormohammadi, J.M. Curtis, T. Baldwin, and A. Sjolander Therapy of murine cutaneous leishmaniasis by DNA vaccination Vaccine 18 26 2000 3011 3017 (Pubitemid 30303805)
283. A.H. Noormohammadi, H. Hochrein, J.M. Curtis, T.M. Baldwin, and E. Handman Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen Vaccine 19 2001 4043 4052 (Pubitemid 32566330)
284. S. Gurunathan, L. Stobie, C. Prussin, D.L. Sacks, N. Glaichenhaus, and D.J. Fowell Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells J Immunol 165 2 2000 915 924 (Pubitemid 30484759)
285. D.C. Gomes, E.F. Pinto, L.D. Melo, W.P. Lima, V. Larraga, and U.G. Lopes Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice Vaccine 25 12 2007 2168 2172 (Pubitemid 46227690)
286. E.A. Marques-da-Silva, E.A. Coelho, D.C. Gomes, M.C. Vilela, C.Z. Masioli, and C.A. Tavares Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge Parasitol Res 98 2005 67 74 (Pubitemid 41670563)
287. P.C. Melby, J. Yang, W. Zhao, L.E. Perez, and J. Cheng Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis Infect Immun 69 2001 4719 4725 (Pubitemid 32674448)
288. S.B.H. Ahmed, L. Touihri, Y. Chtourou, K. Dellagi, and C. Bahloul DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice Vaccine 27 1 2009 99 106
289. R. Gamboa-Leon, E. Paraguai de Souza, G.P. Borja Cabrera, F.N. Santos, L.M. Miyashiro, and R.O. Pinheiro Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani Vaccine 24 22 2006 4863 4873 (Pubitemid 44218848)
290. S. Bhaumik, R. Basu, S. Sen, K. Naskar, and S. Roy KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major Vaccine 27 9 2009 1306 1316
291. F.H.C. Zanin, E.A.F. Coelho, C.A.P. Tavares, E.A. Marques-da-Silva, M.M. Silva Costa, and S.A. Rezende Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections Microbes Infect 9 9 2007 1070 1077 (Pubitemid 47287743)
292. S. Mendez, S. Gurunathan, S. Kamhawi, Y. Belkaid, M.A. Moga, and Y.A. Skeiky The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose intradermal challenge J Immunol 166 2001 5122 5128 (Pubitemid 32280726)
293. O.A. Saldarriaga, B.L. Travi, W. Park, L.E. Perez, and P.C. Melby Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs Vaccine 24 11 2006 1928 1940 (Pubitemid 43238276)
294. R. Pal, V.S. Kalyanaraman, B.C. Nair, S. Whitney, T. Keen, and L. Hocker Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype Virology 348 2006 341 353
295. S. Wang, J.S. Kennedy, K. West, D.C. Montefiori, S. Coley, and J. Lawrence Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers Vaccine 26 2008 1098 1110
296. J.E. Herrmann, S. Wang, C. Zhang, R.G. Panchal, S. Bavari, and C.R. Lyons Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization Vaccine 24 2006 5872 5880 (Pubitemid 43947387)
297. H. Xiao-wen, S. Shu-han, H. Zhen-lin, L. Jun, J. Lei, and Z. Feng-juan Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting Vaccine 23 2005 1649 1656
298. E. Tapia, E. Perez-Jimenez, L. Lopez-Fuertes, R. Gonzalo, M.M. Gherardi, and M. Esteban The combination of DNA vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines followed by a booster with a vaccinia virus recombinant expressing p36/LACK Microbes Infect 5 2003 73 84 (Pubitemid 36316049)
299. L. Lopez-Fuertes, E. Perez-Jimenez, A.J. Vila-Coro, F. Sack, S. Moreno, and S.A. Konig DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice Vaccine 21 2002 247 257 (Pubitemid 35346820)
300. E. Perez-Jimenez, G. Kochan, M.M. Gherardi, and M. Esteban MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis Microbes Infect 8 3 2006 810 822
301. B. Dondji, E. Perez-Jimenez, K. Goldsmith-Pestana, M. Esteban, and D. McMahon-Pratt Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis Infect Immun 73 2005 5286 5289 (Pubitemid 41105698)
302. U.G. Lange, P. Mastroeni, J.M. Blackwell, and C.B. Stober DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice Infect Immun 72 2004 4924 4928 (Pubitemid 38989360)
303. I. Ramos, A. Alonso, J.M. Marcen, A. Peris, J.A. Castillo, and M. Colmenares Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response Vaccine 26 3 2008 333 344
304. C. Carson, M. Antoniou, M.B. Ruiz-Arguello, A. Alcami, V. Christodoulou, and I. Messaritakis A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs the reservoir of zoonotic visceral leishmaniasis Vaccine 27 7 2009 1080 1086
305. S. Rafati, F. Zahedifard, and F. Nazgouee Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis Vaccine 24 12 2006 2169 2175 (Pubitemid 43255160)
306. N. Khoshgoo, F. Zahedifard, H. Azizi, Y. Taslimi, M.J. Alonso, and S. Rafati Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals Vaccine 26 46 2008 5822 5829
307. S. Rafati, F. Zahedifard, M.K. Azari, Y. Taslimi, and T. Taheri Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice Exp Parasitol 118 3 2008 393 401
308. S. Iborra, M. Soto, J. Carrion, A. Nieto, E. Fernandez, and C. Alonso The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice Infect Immun 71 11 2003 6562 6572 (Pubitemid 37337716)
309. C. Bogdan, and M. Rollinghoff How do protozoan parasites survive inside macrophages? Parasitol Today 15 1999 22 28 (Pubitemid 29246041)
310. L.S. Roberts, and J. Janovy Foundations of parasitology 5th ed 1995 Brown/McGraw-Hill Dubuque, IA 68 77
311. A. Descoteaux, and S.J. Turco Glycoconjugates in Leishmania infectivity Biochim Biophys Acta 1455 1999 341 352 (Pubitemid 29435999)
312. L. Miao, A. Stafford, S. Nir, S.J. Turco, T.D. Flanagan, and R.M. Epand Potent inhibition of viral fusion by the lipophosphoglycan of Leishmania donovani Biochemistry 34 1995 4676 4683
313. A.C. Cunningham Parasitic adaptive mechanisms in infection by Leishmania Exp Mol Pathol 72 2002 132 141
314. M.M. Kane, and D.M. Mosser Leishmania parasites and their ploys to disrupt macrophage activation Curr Opin Hematol 7 2000 26 31 (Pubitemid 30007684)
315. A. Descoteaux, S.J. Turco, D.L. Sacks, and G. Matlashewski Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages J Immunol 146 1991 2747 2753
316. M. Olivier, K.G. Baimbridge, and N.E. Reiner Stimulus-response coupling in monocytes infected with Leishmania: attenuation of calcium transients is related to defective agonist-induced accumulation of inositol phosphates J Immunol 148 1992 1188 1196
317. A. Descoteaux, and S.J. Turco The lipophosphoglycan of Leishmania and macrophage protein kinase C Parasitol Today 9 1993 468 471 (Pubitemid 23341201)
318. N.E. Reiner Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection Immunol Today 15 1994 374 381 (Pubitemid 24246911)
319. X.Q. Wei, I.G. Charles, A. Smith, J. Ure, G.J. Feng, and F.P. Huang Altered immune responses in mice lacking inducible nitric oxide synthase Nature 375 1995 408 411
320. J. Alexander, A.R. Satoskar, and D.G. Russell Leishmania species: models of intracellular parasitism J Cell Sci 112 1999 2993 3002 (Pubitemid 29465717)
321. A.L. Sorensen, A.S. Hey, and A. Kharazmi Leishmania major surface protease gp63 interferes with the function of human monocytes and neutrophils in vitro APMIS 102 1994 265 271 (Pubitemid 24185956)
322. E.M. Carvalho, R.S. Teixeira, and W.D. Johnson Jr. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection Infect Immun 33 1981 498 500
323. J.P. Haldar, S. Ghose, K.C. Saha, and A.C. Ghose Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis Infect Immun 42 1983 702 707 (Pubitemid 14230268)
324. M. Ho, D.K. Koech, D.W. Iha, and A.D. Bryceson Immunosuppression in Kenyan visceral leishmaniasis Clin Exp Immunol 51 1983 207 214 (Pubitemid 13177542)
325. P.E. Manson-Bahr Immunity in kala-azar Trans Roy Soc Trop Med Hyg 55 1961 550 555
326. D. Sacks, and N. Noben-Trauth The immunology of susceptibility and resistance to Leishmania major in mice Nat Rev Immunol 2 2002 845 858 (Pubitemid 37328707)
327. T. Kato, H. Yamane, and H. Nariuchi Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages Cell Immunol 181 1997 59 67 (Pubitemid 27519720)
328. M. Munder, M. Mallo, K. Eichmann, and M. Modolell Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation J Exp Med 187 1998 2103 2108 (Pubitemid 28285581)
329. R.J. Armitage, C.R. Maliszewski, M.R. Alderson, K.H. Grabstein, M.K. Spriggs, and W.C. Fanslow CD40L: a multi-functional ligand Semin Immunol 5 1993 401 412
330. C. Brodskyn, C.I. de Oliveira, A. Barral, and M. Barral-Netto Vaccines in leishmaniasis: advances in the last five years Expert Rev Vaccines 2 5 2003 705 717 (Pubitemid 37295366)
331. N.E. Reiner, W. Ng, and W.R. McMaster Parasite-accessory cell interactions in murine leishmaniasis. 2. Leishmania donovani suppresses macrophage expression of class-I and class-II major histocompatibility complex gene-products J Immunol 138 1987 1926 1932 (Pubitemid 17040824)
332. N.E. Reiner, W. Ng, T. Ma, and W.R. McMaster Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania-infected macrophages Proc Natl Acad Sci U S A 85 12 1988 4330 4334
333. M.C. De Almeida, S.A. Cardoso, and M. Barral-Netto Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage Int J Parasitol 33 2003 153 162 (Pubitemid 36298986)
334. U. Fruth, N. Solioz, and J.A. Louis Leishmania major interferes with antigen presentation by infected macrophages J Immunol 150 1993 1857 1864 (Pubitemid 23129662)
335. E. Prina, C. Jouanne, L.S. de Souza, A. Szabo, J.G. Guillet, and J.C. Antoine Antigen presentation capacity of murine macrophages infected with Leishmania amazonensis amastigotes J Immunol 151 1993 2050 2061 (Pubitemid 23235677)
336. C. Bogdan, A. Gessner, W. Solbach, and M. Rollinghoff Invasion, control and persistence of Leishmania parasites Curr Opin Immunol 8 1996 517 525 (Pubitemid 26280781)
337. F.P. Heinzel, R.M. Rerko, and A.M. Hujer Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity Cell Immunol 184 1998 124 142
338. M. Kobayashi, L. Fitz, M. Ryan, R.M. Hewick, S.C. Clark, and S. Chan Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes J Exp Med 170 1989 827 845 (Pubitemid 19226667)
339. A.S. Stern, F.J. Podlaski, J.D. Hulmes, Y.C. Pan, P.M. Quinn, and A.G. Wolitzky Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells Proc Natl Acad Sci U S A 87 17 1990 6808 6812
340. S.H. Chan, M. Kobayashi, D. Santoli, B. Perussia, and G. Trinchieri Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2 J Immunol 148 1992 92 98
341. P. Scott IL-12: initiation cytokine for cell-mediated immunity Science 260 5107 1993 496 497 (Pubitemid 23161612)
342. G. Trinchieri Interleukin-12 and its role in the generation of TH1 cells Immunol Today 14 1993 335 338 (Pubitemid 23198164)
343. F.P. Heinzel, D.S. Schoenhaut, R.M. Rerko, L.E. Rosser, and M.K. Gately Recombinant interleukin 12 cures mice infected with Leishmania major J Exp Med 177 1993 1505 1509 (Pubitemid 23117143)
344. J.P. Sypek, C.L. Chung, S.E.H. Mayor, J.M. Subramanyam, S.J. Goldman, and D.S. Sieburth Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective Th1 immune response J Exp Med 177 1993 1797 1802 (Pubitemid 23146148)
345. S.E. Macatonia, C.S. Hsieh, K.M. Murphy, and A. O'Garra Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha-beta-TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-g dependent Int Immunol 5 1993 1119 1128 (Pubitemid 23291161)
346. T. Tanaka, J. Hu Li, R.A. Seder, B. Fazekas de st Groth, and W.E. Paul Interleukin 4 suppresses interleukin 2 and interferon-γ production by naïve T cells stimulated by accessory cell-dependent receptor engagement Proc Natl Acad Sci U S A 90 1993 5914 5918 (Pubitemid 23191424)
347. A.Y. Park, B. Hondowicz, M. Kopf, and P. Scott The role of IL-12 in maintaining resistance to Leishmania major J Immunol 168 2002 5771 5777 (Pubitemid 34556162)
348. L. Carrera, R.T. Gazzinelli, R. Badolato, S. Hieny, W. Muller, and R. Kuhn Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice J Exp Med 183 2 1996 515 526 (Pubitemid 26059515)
349. P.M. Gorak, C.R. Engwerda, and P.M. Kaye Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection Eur J Immunol 28 1988 687 695
350. E. Von Stebut, Y. Belkaid, T. Jakob, D.L. Sacks, and M.C. Udey Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin derived dendritic cells: implications for the initiation of anti-Leishmania immunity J Exp Med 188 1998 1547 1552 (Pubitemid 28489593)
351. P. Konecny, A.J. Stagg, H. Jebbari, N. English, R.N. Davidson, and S.C. Knight Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12p40 and stimulate primary T cell proliferation in vitro Eur J Immunol 29 1999 1803 1811 (Pubitemid 29265535)
352. M.A. Marovich, M.A. McDowell, E.K. Thomas, and T.B. Nutman IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process J Immunol 164 2000 5858 5865 (Pubitemid 30389830)
353. M. Quinones, S.K. Ahuja, P.C. Melby, L. Pate, R.L. Reddick, and S.S. Ahuja Preformed membrane associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite J Exp Med 192 2000 507 516
354. A. Snijders, P. Kalinski, C.M. Hilkens, and M.L. Kapsenberg High-level IL-12 production by human dendritic cells requires two signals Int Immunol 10 1998 1593 1598 (Pubitemid 28502373)
355. M.K. Ghosh, A. Nandy, M. Addy, T.K. Maitra, and A.C. Ghose Subpopulations of T lymphocytes in the peripheral blood, dermal lesions and lymph nodes of post kala-azar dermal leishmaniasis patients Scand J Immunol 41 1995 11 17
356. A.B. Neogy, A. Nandy, B. Ghosh Dastidar, and A.B. Chowdhury Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy Ann Trop Med Parasitol 82 1988 27 34
357. H.W. Murray Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis J Infect Dis 175 6 1997 1477 1479 (Pubitemid 27225053)
358. M.T.M. Roberts Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment Br Med Bull 75-76 2006 115 130 (Pubitemid 44725919)
359. Z.E. Wang, S.L. Reiner, S. Zheng, D.K. Dalton, and R.M. Locksley CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major J Exp Med 179 1994 1367 1371 (Pubitemid 24091797)
360. P. Scott IFN-γ modulates the early development of Th1 & Th2 response in murine model of cutaneous leishmaniasis J Immunol 147 1991 3149 3155
361. K. Swihart, U. Fruth, N. Messmer, K. Hug, R. Behin, and S. Huang Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response J Exp Med 181 1995 961 971
362. M. Belosevic, D.S. Finbloom, P.H. Van Der Meide, M.V. Slayter, and C.A. Nacy Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major J Immunol 143 1989 266 274 (Pubitemid 19174230)
363. M.C. Tumang, T.C. Keogh, L.L. Moldawer, D.C. Helfgott, R. Teitlbaum, and J. Hariprashad Role and effect of TNF-α in experimental visceral leishmaniasis J Immunol 153 1994 768 775
364. P. Wilhelm, U. Ritter, S. Labbow, N. Donhauser, M. Rollinghoff, and C. Bogdan Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF J Immunol 166 2001 4012 4019 (Pubitemid 32224930)
365. C. Theodos, M.L. Povinelli, R. Mollina, B. Sherry, and R.G. Titus Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo Infect Immun 59 1991 2839 2842
366. P.P. Manna, G. Chakrabarti, and S. Bandyopadhyay Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogenic effector cell Vaccine 28 3 2010 803 810
367. F.Y. Liew, C. Parkinson, S. Millott, A. Severn, and M. Carrier Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis Immunology 69 1990 570 573 (Pubitemid 20123610)
368. V. Kindler, A.P. Sappino, G.E. Grau, P.F. Piguet, and P. Vassalli The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection Cell 56 1989 731 740 (Pubitemid 19082507)
369. R. de Waal Malefyt, J. Abrams, B. Bennett, C.G. Figdor, and J.E. De Vries Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes J Exp Med 174 1991 1209 1220
370. A. Ribeiro-de-Jesus, R.P. Almeida, H. Lessa, O. Bacellar, and E.M. Carvalho Cytokine profile and pathology in human leishmaniasis Braz J Med Biol Res 31 1998 143 148 (Pubitemid 128524624)
371. P. Tripathi, V. Singh, and S. Naik Immune response to Leishmania: paradox rather than paradigm FEMS Immunol Med Microbiol 51 2007 229 242 (Pubitemid 47547509)
372. H.W. Ghalib, M.R. Piuvezam, Y.A. Skeiky, M. Siddig, F.A. Hashim, and A.M. El-Hassan Interleukin 10 production correlates with pathology in human Leishmania donovani infections J Clin Invest 92 1 1993 324 329 (Pubitemid 23209013)
373. E.M. Carvalho, O. Bacellar, C. Brownell, T. Regis, R.L. Coffman, and S.G. Reed Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis J Immunol 152 1994 5949 5956
374. I.P. Oswald, T.A. Wynn, A. Sher, and S.L. James Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma induced activation Proc Natl Acad Sci 89 1992 8676 8680
375. A. D'Andrea, M. Aste-Amezaga, N.M. Valiante, X. Ma, M. Kubin, and G. Trinchieri Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells J Exp Med 178 1993 1041 1048 (Pubitemid 23260442)
376. L. Ding, P.S. Linsley, L.-Y. Huang, R.N. Germain, and E.M. Shevach IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression J Immunol 151 3 1993 1224 1234 (Pubitemid 23219258)
377. B. Saha, G. Das, H. Vohra, N.K. Ganguly, and G.C. Mishra Macrophage T cell interaction in experimental visceral leishmaniasis: failure to express co-stimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity Eur J Immunol 25 1995 2494 2498
378. M. Kubin, M. Kamoun, and G. Trinchieri Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells J Exp Med 180 1994 211 222 (Pubitemid 24181070)
379. H.W. Ghalib, J.A. Whittle, M. Kubin, F.A. Hashim, and A.M. El-Hassan Interleukin-12 enhances Th1-type responses in human Leishmania donovani infections J Immunol 154 1995 4623 4629
380. J. Alexander, and K. Bryson T helper (h)1/Th2 and Leishmania: paradox rather than paradigm Immunol Lett 99 1 2005 17 23 (Pubitemid 40718928)
381. M.E. Wilson, S.M. Jeronimo, and R.D. Pearson Immunopathogenesis of infection with the visceralizing Leishmania species Microb Pathog 38 2005 147 160 (Pubitemid 40417730)
382. W.H. Boom, L. Liebster, A.K. Abbas, and R.G. Titus Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution Infect Immun 58 12 1990 3863 3870
383. F.Y. Liew, S. Millott, Y. Li, R. Lelchuk, W.L. Chan, and H. Ziltener Macrophage activation by interferon-γ from host protective T cell is inhibited by interleukin (IL) 3 and IL 4 produced by disease promoting T cells in leishmaniasis Eur J Immunol 19 1989 1227 1232 (Pubitemid 19196900)
384. M. Kopf, F. Brombacher, G. Kohler, G. Kienzle, K.H. Widmann, and K. Lefrang IL-4-deficient BALB/c mice resist infection with Leishmania major J Exp Med 184 3 1996 1127 1136 (Pubitemid 26313569)
385. K. Zwingenberger, G. Harms, C. Pedrosa, S. Omena, B. Sandkamp, and S. Neifer Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon gamma production Clin Immunol Immunopathol 57 1990 242 249 (Pubitemid 20368037)
386. S. Sundar, S.G. Reed, S. Sharma, A. Mehrotra, and H.W. Murray Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis Am J Trop Med Hyg 56 1997 522 525 (Pubitemid 27230074)
387. R.T. Kenney, D.L. Sacks, A.A. Gam, H.W. Murray, and S. Sundar Splenic cytokine responses in Indian kala-azar before and after treatment J Infect Dis 177 1998 815 818
388. E. Cillari, F.Y. Liew, P. Lo Campo, S. Milano, S. Mansueto, and A. Salerno Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily J Immunol 140 1988 2721 2726
389. Z. Babaloo, P.M. Kaye, and M.B. Eslami Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines Trans R Soc Trop Med Hyg 95 2001 85 88 (Pubitemid 34202236)
390. O. Bacellar, A. D'oliveira Jr., S. Jeronimo, and E.M. Carvalho IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis Cytokine 12 2000 1228 1231 (Pubitemid 30611800)
391. M. Mohrs, C. Holscher, and F. Brombacher Interleukin-4 receptor alphadeficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection Infect Immun 68 2000 1773 1780 (Pubitemid 30164798)
392. T. Biedermann, S. Zimmermann, H. Himmelrich, A. Gumy, O. Egeter, and A.K. Sakrauski IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice Nat Immunol 2 2001 1054 1060 (Pubitemid 33069501)
393. S. Stager, J. Alexander, K.C. Carter, F. Brombacher, and P.M. Kaye Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity Infect Immun 71 2003 4804 4807 (Pubitemid 36919951)
394. S. Stager, J. Alexander, A.C. Kirby, M. Botto, N.V. Rooijen, and D.F. Smith Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses Nat Med 9 2003 1287 1292 (Pubitemid 37279852)
395. J.H. Kehrl, A.B. Roberts, L.M. Wakefield, S. Jakowlew, M.B. Sporn, and A.S. Fauci Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes J Immunol 137 1986 3855 3860 (Pubitemid 17215314)
396. J.H. Kehrl, L.M. Wakefield, A.B. Roberts, S. Jakowlew, M. Alvarez-Mon, and R. Derynck Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth J Exp Med 163 1986 1037 1050 (Pubitemid 16000407)
397. A. Ding, C.F. Nathan, J. Graycar, R. Derynck, D.J. Stuehr, and S. Srimal Macrophage deactivating factor and transforming growth factors β1, β2, and β3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ J Immunol 145 1990 940 944 (Pubitemid 20231287)
398. S. Tsunawaki, M. Sporn, A. Ding, and C.F. Nathan Deactivation of macrophages by transforming growth factor β Nature 334 1988 260 262
399. F.M. Omer, J.A.L. Kurtzhals, and E.M. Riley Maintaining the immunological balance in parasitic infections: a role for TGF-β? Parasitol Today 16 2000 18 23 (Pubitemid 30101611)
400. I.M. Corraliza, G. Soler, K. Eichmann, and M. Modolell Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone marrow-derived macrophages Biochem Biophys Res Commun 206 1995 667 673
401. S.M. Wahl Transforming growth factor-β: the good, the bad and the ugly J Exp Med 180 1994 1587 1590 (Pubitemid 24328550)
402. Y. Vodovotz, C. Bogdan, J. Paik, Q.W. Xie, and C. Nathan Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β J Exp Med 178 1993 605 613 (Pubitemid 23218209)
403. S. Stenger, H. Thuring, M. Rollinghoff, and C. Bogdan Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major J Exp Med 180 1994 783 793 (Pubitemid 24256592)
404. T. Scharton-Kersten, L.C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis J Immunol 154 1995 5320 5330
405. A. Barral, M. Barral-Netto, E.C. Yong, C.E. Brownell, D.R. Twardzik, and S.G. Reed Transforming growth factor β as a virulence mechanism for Leishmania braziliensis Proc Natl Acad Sci U S A 90 1993 3442 3446 (Pubitemid 23111382)
406. A. Barral, M. Teixeira, P. Reis, V. Vinhas, J. Costa, and H. Lessa Transforming growth factor β in human cutaneous leishmaniasis Am J Pathol 147 1995 947 954
407. M. Barral-Netto, A. Barral, C.E. Brownell, Y.A. Skeiky, L.R. Ellingsworth, and D.R. Twardzik Transforming growth factor β in Leishmania infection: a parasite escape mechanism Science 257 1992 545 548
408. V. Rodrigues Jr., J.S. Da Silva, and Campos-Neto Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis Infect Immun 66 3 1998 1233 1236 (Pubitemid 28101169)
409. K.R. Gantt, S. Schultz-Cherry, N. Rodriguez, S.M.B. Jeronimo, E.T. Nascimento, and T.L. Goldman Activation of TGF-{beta} by Leishmania chagasi: importance for parasite survival in macrophages J Immunol 170 2003 2613 2620 (Pubitemid 36245653)